Pharmacotherapy of panic disorder

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 4, 2008, Pages 779-795

  Pull, Charles B ^a   Damsa, Cristian ^b  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Agoraphobia; Cognitive behavioral therapy; Combination treatments; Panic disorder; Pharmacotherapy

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NOOTROPIC AGENT; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADD ON THERAPY; AGORAPHOBIA; ANXIETY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEALTH CARE COST; HUMAN; INTERNET; LONG TERM CARE; MAINTENANCE THERAPY; MEMORY DISORDER; MONOTHERAPY; NONHUMAN; PANIC; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SELF CARE; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRTUAL REALITY; WEAKNESS; XEROSTOMIA;

EID: 52649158796     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1224     Document Type: Review

References (68)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, IVth edn, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
2. Asnis GM, Hameedi FA, Goddard AW, et al. 2001. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res, 103:1-14.
3. Bakish D, Hooper CL, Filteau MJ, et al. 1996. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacoly Bull, 32:135-41.
4. Bakish D, Saxena BM, Bowen R, et al. 1993. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacology, 16:77-82.
5. Bakker A, van Balkom AJ, Spinhoven P. 2002. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatrica Scand, 106:163-7.
6. Ballenger JC, Wheadon DE, Steiner M, et al. 1998. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry, 155:36-42.
7. Bandelow B, Behnke K, Lenoir S, et al. 2004. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry, 65:405-13.
8. Black DW, Wesner R, Bowers W, et al. 1993. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry, 50:44-50.
9. Botella C, Villa H, Garcia-Palacios A, et al. 2004a. The use of virtual reality in the treatment of panic and agoraphobia. In: G. Riva, C. Botella, P. Légeron, G. Optale (Eds.). Cybertherapy: Internet and virtual reality as assessment and rehabilitation tools for clinical psychology and neuroscience. Amsterdam: Ios Press.
10. Botella C, Villa H, Garcia Palacios A, et al. 2004b. The use of VR in the treatment of panic disorders and agoraphobia. Stud Health Techn Informatics, 99:73-90.
11. Bradwejn J, Ahokas A, Stein DJ, et al. 2005. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry, 187:352-9.
12. Bruce SE, Vasile RG, Goisman RM et al. 2003. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry, 160:1432-38.
13. Butler AC, Chapman JE, Forman EM, et al. 2006. The empirical status of cognitive-behavioural therapy: a review of meta-analyses. Clin Psychol Rev, 26:17-31.
14. Carlbring P, Bohman S, Brunt S, et al. 2006. Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry, 163:2119-25.
15. Chouinard G. 2004. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry, 65:7-12.
16. Craske MG, Farchione TJ, Allen LB, et al. 2006. Cognitive behavioural therapy for panic disorder and comorbidity: More of the same or less of more? Behav Res Ther, 45:1095-109.
17. Dannon PN, Iancu I, Cohen A, et al. 2004. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry, 4:16.
18. Fava GA, Ruini C, Rafanelli C. 2005. Sequential treatment of mood and anxiety disorders. J Clin Psychiatry, 66:1392-400.
19. Furukawa TA, Watanabe N, Churchill R. 2006. Psychotherapy plus anti-depressant for panic disorder with or without agoraphobia: Systematic review. Br J Psychiatry, 188:305-12.
20. Gould RA, Otto MW, Pollack MH. 1995. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Review, 15:819-44.
21. Heldt E, Gus Manfro G, Kipper L, et al. 2006. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: Outcome and predictors of remission. Behav Res Therapy, 44:657-65.
22. Hoehn-Saric R, McLeod DR, Hipsley PA. 1993. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacology, 13:321-6.
23. Kampman M, Keijsers GPJ, Hoogduin CAL, et al. 2002. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioural therapy alone. J Clin Psychiatry, 63:772-7.
24. Katon W, Russo J, Sherbourne C, et al. 2006. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychological Medicine, 36:353-63.
25. Kessler RC, Chiu WT, Jin R, et al. 2006. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 63:415-4.
26. Klein DF. 1964. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5:397-408.
27. Kruger MB, Dahl AA. 1999. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psych Clin Neurosciences, 249:19-24.
28. Lecrubier Y, Bakker A, Dunbar G, et al. 1997. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand, 95:145-52.
29. Lecrubier Y, Judge R. 1997. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand, 95:153-60.
30. Lepola UM, Wade AG, Leinonen EV, et al. 1998. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry, 59:528-34.
31. Londborg PD, Wolkow R, Smith WT, et al. 1998. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry, 173:54-60.
32. Marcus SM, Gorman J, Shear MK, et al. 2007. A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. Am J Psychiatry, 164:273-5.
33. Mavissakalian MR. 2003. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry, 15:171-80.
34. Mavissakalian MR, Perel JM. 1999. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry, 56:821-7.
35. Mavissakalian MR, Perel JM. 2002. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol, 22:294-9.
36. Michelson D, Allgulander C, Dantendorfer K, et al. 2001. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry, 179:514-8.
37. Michelson D, Lydiard RB, Pollack MH, et al. 1998. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry, 155:1570-7.
38. Michelson D, Pollack M, Lydiard RB, et al. 1999. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry, 174:213-8.
39. Mitte K. 2005. A meta-analysis of the efficacy of psycho-and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord, 88:27-45.
40. Oehrberg S, Christiansen PE, Behnke K, et al. 1995. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry, 167:374-9.
41. Otto MW, Powers M, Struts JASD. 2005. Adding cognitive-behavioural therapy to pharmacotherapy for panic disorder: issues and strategies. CNS Spectrums, 9:32-9.
42. Pohl RB, Wolkow RM, Clary CM. 1998. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry, 155:1189-95.
43. Pollack MH, Lepola U, Koponen H, et al. 2007. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety, 24:1-14.
44. Pollack MH, Otto MW, Worthington JJ, et al. 1998. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry, 55:1010-16.
45. Pollack MH, Simon NM, Worthington JJ, et al. 2003. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacology, 17:276-82.
46. Pollack MH, Worthington JJ 3rd, Otto MW, et al. 1996. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull, 32:667-70.
47. Pull CB, Cottraux J, Berthoz A, et al. 2006. Randomized controlled study of virtual reality exposure therapy and cognitive-behaviour therapy in panic disorder with agoraphobia. Cyberpsychol Behav, 9:712.
48. Pull CB. 2005. Current status of virtual reality exposure therapy in anxiety disorders: editorial review. Curr Opin Psychiatry, 18:7-14.
49. Pull CB. 2006. Self-help interventions for the treatment of anxiety disorders. Curr Opin Psychiatry, 19:50-3.
50. Pull CB. 2007. Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr Opin Psychiatry, 20:30-5.
51. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. 2004. Cognitive Enhancers as Adjuncts to Psychotherapy. Use of D-Cycloserine in Phobic Individuals to Facilitate Extinction of Fear. Arch Gen Psychiatry, 61:1136-44.
52. Rickels K, Schweizer E, Weiss S, et al. 1993. Maintenance drug treatment for panic disorder. II Short- and long-term outcome after drug taper. Arch Gen Psychiatry, 50:61-8.
53. Riederer P, Lachenmayer L, Laux G. 2004. Clinical applications of MAO-inhibitors. Curr Med Chem, 11:2033-43.
54. Rollman BL, Belnap BH, Mazumdar S, et al. 2003. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch Gen Psychiatry, 62:1332-41.
55. Rosenbaum JF. 2004. The development of clonazepam as a psychotropic: the massachusetts general hospital experience. J Clin Psychiatry, 65:3-6.
56. Roy-Byrne PP, Cowley DS. 2002. Pharmacologic treatment for panic disorder, generalized anxiety disorder, specific phobia and social anxiety disorders. In: Nathan P, Gorman JM (eds). A guide to treatments that work. Second Edition. New York: Oxford University Press, pp. 337-65.
57. Roy-Byrne PP, Craske MG, Stein MB, et al. 2005. A randomized effectiveness trial of cognitive-behavioural therapy and medication for primary care panic disorder. Arch Gen Psychiatry, 62:290-8.
58. Roy-Byrne PP, Craske MG, Stein MB. 2006. Panic disorder. Lancet, 368:1023-32.
59. Schweizer E, Pohl R, Balon R, et al. 1990. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry, 23:90-3.
60. Sheehan DV, Burnham DB, Iyengar MK, et al. 2005. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry, 66:34-40.
61. Sheikh JI, Londborg P, Clary CM, et al. 2000. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol, 15:335-42.
62. Stahl SM, Gergel I, Li D. 2003. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 64:1322-7.
63. Tiller JW, Bouwer C, Behnke K. 1999. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psych Clin Neurosciences, 249:7-10.
64. Toni C, Perugi G, Frare F, et al. 2000. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry, 33:121-31.
65. Van Vliet IM, den Boer JA, Westenberg HG, et al. 1996. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol. 16:299-306.
66. Verster JC, Volkerts ER. 2004. Clinical pharmacology, clinical efficacy, and behavioural toxicity of alprazolam: a review of the literature. CNS Drug Rev, 10:45-76.
67. Wade AG, Lepola U, Koponen HJ, et al. 1997. The effect of citalopram in panic disorder. Br J Psychiatry, 170:549-53.
68. Westen D, Morrison K. 2001. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol, 69:875-99.